228 related articles for article (PubMed ID: 19960212)
1. Critical role of transglutaminase and other stress proteins during neurodegenerative processes.
Caccamo D; Currò M; Condello S; Ferlazzo N; Ientile R
Amino Acids; 2010 Feb; 38(2):653-8. PubMed ID: 19960212
[TBL] [Abstract][Full Text] [Related]
2. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
Wilhelmus MM; van Dam AM; Drukarch B
Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase is linked to neurodegenerative diseases.
Muma NA
J Neuropathol Exp Neurol; 2007 Apr; 66(4):258-63. PubMed ID: 17413316
[TBL] [Abstract][Full Text] [Related]
5. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking.
Konno T; Morii T; Hirata A; Sato S; Oiki S; Ikura K
Biochemistry; 2005 Feb; 44(6):2072-9. PubMed ID: 15697232
[TBL] [Abstract][Full Text] [Related]
6. The multifaceted role of transglutaminase in neurodegeneration: review article.
Karpuj M; Steinman L
Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
[TBL] [Abstract][Full Text] [Related]
7. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications.
Williams A; Jahreiss L; Sarkar S; Saiki S; Menzies FM; Ravikumar B; Rubinsztein DC
Curr Top Dev Biol; 2006; 76():89-101. PubMed ID: 17118264
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
Hol EM; Fischer DF; Ovaa H; Scheper W
Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
[TBL] [Abstract][Full Text] [Related]
9. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
[TBL] [Abstract][Full Text] [Related]
10. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.
Ross CA; Pickart CM
Trends Cell Biol; 2004 Dec; 14(12):703-11. PubMed ID: 15564047
[TBL] [Abstract][Full Text] [Related]
11. Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
Bailey CD; Graham RM; Nanda N; Davies PJ; Johnson GV
Mol Cell Neurosci; 2004 Mar; 25(3):493-503. PubMed ID: 15033177
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
13. Heat shock proteins as suppressors of accumulation of toxic prefibrillar intermediates and misfolded proteins in neurodegenerative diseases.
Arawaka S; Machiya Y; Kato T
Curr Pharm Biotechnol; 2010 Feb; 11(2):158-66. PubMed ID: 20170473
[TBL] [Abstract][Full Text] [Related]
14. Stress proteins in Alzheimer's disease.
Smith RC; Rosen KM; Pola R; Magrané J
Int J Hyperthermia; 2005 Aug; 21(5):421-31. PubMed ID: 16048839
[TBL] [Abstract][Full Text] [Related]
15. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration.
Uehara T; Nakamura T; Yao D; Shi ZQ; Gu Z; Ma Y; Masliah E; Nomura Y; Lipton SA
Nature; 2006 May; 441(7092):513-7. PubMed ID: 16724068
[TBL] [Abstract][Full Text] [Related]
16. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
Gallardo G; Schlüter OM; Südhof TC
Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
[TBL] [Abstract][Full Text] [Related]
17. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
Rockenstein E; Crews L; Masliah E
Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
Grosso H; Mouradian MM
Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
[TBL] [Abstract][Full Text] [Related]
19. A single amino acid substitution in a proteasome subunit triggers aggregation of ubiquitinated proteins in stressed neuronal cells.
Li Z; Arnaud L; Rockwell P; Figueiredo-Pereira ME
J Neurochem; 2004 Jul; 90(1):19-28. PubMed ID: 15198663
[TBL] [Abstract][Full Text] [Related]
20. Structure and function of the molecular chaperone Hsp104 from yeast.
Grimminger-Marquardt V; Lashuel HA
Biopolymers; 2010 Mar; 93(3):252-76. PubMed ID: 19768774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
